Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Article
Change log
Authors
Azizi, Alexander A.
Hadjinicolaou, Andreas V.
Goncalves, Carla
Duckworth, Adam
Basu, Bristi
Abstract
Combined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international guidelines for optimal management. For localized tumors, radical resection represents the preferred treatment option, whereas for advanced tumors, systemic therapies recommended for intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are often selected. Emerging information from comparative cohort studies, genomic and transcriptomic data sets are starting to build a case for rationalized approaches to systemic treatment in the advanced setting specific to cHCC-ICC.
Description
Keywords
Oncology, Combined hepatocellular-cholangiocarcinoma, cHCC-ICC, cHCC-CCA, biphenotypic, primary liver cancer, genomics, systemic therapy
Journal Title
Frontiers in Oncology
Conference Name
Journal ISSN
2234-943X
Volume Title
10
Publisher
Frontiers Media S.A.